21 July 2022. The Rapid Core CRF is designed to collect data obtained through examination, interview and review of
hospital or clinic notes of patients with suspected, probable, or confirmed monkeypox infection. Data
may be collected prospectively or retrospectively. The data collection period is ...defined as the period
from hospital admission or first clinic visit to discharge from care, transfer, death, or continued
hospitalization without possibility of continued data collection.
more
The EYE communication strategy is intended for use by all EYE partners and respective communication teams, as well as regional and country colleagues who will need to communicate about the work of EYE. It will also be publicly available for others, ...such as non-governmental organizations (NGOs) and private sector organizations, who may wish to read or share content published about EYE.
more
This annual report highlights the work of the WHO from January to June 2021 ( December 2021). The activities featured herein are by no means exhausted but implemented with technical and financial support through ...edbox">WHO in Nigeria; facilitated by its presence at all levels of governance (national, state, local government, and wards).
more
The Greater Horn of Africa is experiencing one of the worst food insecurity situations in decades. It is estimated
that more than 37 million people are in Integrated Food Security Phase Classification (IPC)1 phase 3 or above and approximately 7 million children under the age of five are acutely mal...nourished in the region. While finding food and safe water is the absolute priority, the health response is essential to avert preventable disease and death.
more
The pandemic has emphasized the high risk of avoidable harm to patients, health workers, and the general public, and has identified a range of safety gaps across all core components of health system...s at all levels.
The rapid review ‘Implications of the COVID-19 pandemic for patient safety’ explores impacts that the COVID-19 pandemic did have on patient safety in terms of risks and avoidable harm, specifically in terms of diagnostic, treatment and care management related issues as well as highlights the main patterns of these implications within the broader health system context.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, admi...nistering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
more
Resource platform.
The Global Atlas of medical devices (GAMD) provides global, regional and country data on availability of:
national policy on health technology
regulation of medical devices
...x">health technology assessment national unit
health technology management
use of medical devices nomenclature system
national lists of priority medical devices
high cost medical equipment.
more
This is the first edition of Empiric Antibiotic Guidelines, as a guidance to all medical practitioners at North Okklapa General & Teaching Hospital.
Antibiotics are critical in the management of infection and can have a significant impact in reducing morbidity and mortality. Emerging antimicrobia...l resistance has been identified as global challenge by the World Health Organization. Careful use of antibiotics targeted to likely pathogens is an important strategy in combating development of antimicrobial resistance.
more
The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the op...timal care of patients with EVD throughout their illness is important.
The living guidance is available in both pdf format (via the ‘Download’ button) and via an online platform in both French and English, and is updated regularly as new evidence emerges.
This first version of the Clinical management for EVD living guidance contains four new recommendations regarding use of therapeutics for EVD, this includes two strong recommendations for the use of monoclonal antibody therapies. This new living guideline is written to accompany the optimized supportive care (oSoC) for EVD standard operating procedures (5, 6). The living guideline aims to summarize high quality evidence for EVD therapeutics and make recommendations for their use.
more